Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids

Journal of Drug Targeting

Volumn 13, Issue 1, 2005, Pages 73-80

  Wang, Junping ^a   Mongayt, Dimitry ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cationic lipids; In vitro anticancer effect; Mixed micelles; Paclitaxel; PEG PE; Polymeric micelles

Indexed keywords

LIPID; LIPOFECTIN; MACROGOL; MACROGOL DISTEAROYL PHOSPHOETHANOLAMINE CONJUGATE; PACLITAXEL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; ROOM TEMPERATURE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMISTRY; HUMANS; LIPIDS; MICELLES; MICROSCOPY, FLUORESCENCE; PACLITAXEL; POLYETHYLENE GLYCOLS; SOLUBILITY; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 14644405045     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400011935     Document Type: Article

References (56)

1. Almofti MR, Harashima H, Shinohara Y, Almofti A, Baba Y, Kiwada H. 2003. Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization, Arch Biochem Biophys 410:246-253.
2. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res 58:2825-2831.
3. Chawla JS, Amiji MM. 2002. Biodegradable poly(epsilon-capro-lactone) nanoparticles for tumor-targeted delivery of tamoxifen, Int J Pharm 249:127-138.
4. Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, Wentzel B, Kessler D, Worah D, Quay SC. 2000. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel, Pharm Res 17:175-182.
5. Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, Garbagnati F, Spreafico C, Ticha V, Gladin CR, Palazzi M, Crippa F, Oldini C, Calo S, Bonaccorsi A, Mattavelli F, Costa L, Mariani L, Cantu G. 2003. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings, Am J Roentgenol 181:253-260.
6. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL. 1994. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations, J Biol Chem 269:2550-2561.
7. Filion MC, Phillips NC. 1997. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells, Biochim Biophys Acta 1329:345-356.
8. Fjallskog ML, Frii L, Bergh J. 1993. Is Cremophor EL, solvent for paclitaxel, cytotoxic?, Lancet 342:8873-8875.
9. Gabizon AA. 1995. Liposome circulation time and tumor targeting - implications for cancer-chemotherpy, Adv Drug Deliv Rev 16:285-294.
10. Gao Z, Lukyanov AN, Singhal A, Torchilin VP. 2002. Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs, Nano Lett 2:979-982.
11. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. 2003. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing, J Drug Targ 11:87-92.
12. Hafez IM, Maurer N, Cullis PR. 2001. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids, Gene Ther 8:1188-1196.
13. He L, Wang GL, Zhang Q. 2003. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile, Int J Pharm 250:45-50.
14. Horwitz SB. 1994. Taxol (paclitaxel): mechanisms of action, Ann Oncol 5(Suppl. 6), S3-S6.
15. Iakoubov LZ, Torchilin VP. 1997. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice, Oncol Res 9:439-446.
16. Jones M, Leroux J. 1999. Polymeric micelles - a new generation of colloidal drug carriers, Eur J Pharmacol Biopharmacol 48:101-111.
17. Jordan MA. 2002. Mechanism of action of antitumor drugs that interact with microtubules and tubulin, Curr Med Chem Anti-Canc Agents 2:1-17.
18. Kaiser S, Toborek M. 2003. High-efficiency transfection of human endothelial cells mediated by cationic lipids, J Vasc Res 38:133-143.
19. Kallio H, Laakso P, Huopalahti R, Linko RR, Oksman P. 1989. Analysis of butter fat triacylglycerols by supercritical fluid chromatography/electron impact mass spectrometry, Anal Chem 61:698-700.
20. Kan P, Chen ZB, Lee CJ, Chu IM. 1999. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system, J Control Release 58:271-278.
21. Krishnadas A, Rubinstein I, Onyuksel H. 2003. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs, Pharm Res 20:297-302.
22. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. 2003. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model, J Invest Dermatol 120:476-482.
23. Kwon GS, Kataoka K. 1995. Block-copolymer micelles as long-circulating drug vehicles, Adv Drug Deliv Rev 16:295-309.
24. Lasic DD. 1992. Mixed micelles in drug delivery, Nature 355:279-280.
25. Legendre JY, Szoka FC, Jr.. 1992. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes, Pharm Res 9:1235-1242.
26. Liggins RT, Burt HM. 2002. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations, Adv Drug Deliv Rev 54:191-202.
27. Ling YH, Yang Y, Tornos C, Singh B, Perez-Soler R. 1998. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells, Cancer Res 58:3633-3640.
28. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. 2002. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice, Pharm Res 19:1424-1429.
29. Lukyanov AN, Gao Z, Torchilin VP. 2003a. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery, J Control Release 91:97-102.
30. Lukyanov AN, Hartner WC, Torchilin VP. 2003b. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits, J Control Release, in press.
31. Lundberg BB. 1997. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol), J Pharm Pharmacol 49:16-21.
32. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J Control Release 65:271-284.
33. Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J Control Release 74:47-61.
34. Mitra A, Lin S. 2003. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems, J Pharm Pharmacol 55:895-902.
35. Muranishi S. 1990. Absorption enhancers, Crit Rev Ther Drug Carrier Syst 7:1-33.
36. Nassberger L, Bergstrand A, DePierre JW. 1991. An electron and fluorescence microscopic study of LLC-PK1 cells, a kidney epithelial cell line: normal morphology and cyclosporin A- and cremophor-induced alterations, Int, J Exp Pathol 72:365-378.
37. Ni R, Nishikawa Y, Carr BI. 1998. Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation, J Biol Chem 273:9906-9911.
38. Ota T, Maeda M, Tatsuka M. 2002. Cationic liposomes with plasmid DNA influence cancer metastatic capability, Anticancer Res 22:4049-4052.
39. Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V. 1984. The mechanism of liposome accumulation in infarction, Biochim Biophys Acta 797:363-368.
40. Potineni A, Lynn DM, Langer R, Amiji MM. 2003. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery, J Control Release 86:223-234.
41. Rodrigues DG, Covolan CC, Coradi ST, Barboza R, Maranhao RC. 2002. Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel, J Pharm Pharmacol 54:765-772.
42. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. 1993. Clinical toxicities encountered with paclitaxel (Taxol), Semin Oncol 20(4 Suppl. 3), 1-15.
43. Sakurai F, Inoue R, Nishino Y, Okuda A, Matsumoto O, Taga T, Yamashita F, Takakura Y, Hashida M. 2000. Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression, J Control Release 66:255-269.
44. Sarosy G, Reed E. 1993. Taxol dose intensification and its clinical implications, J Natl Med Assoc 85:427-431.
45. Torchilin VP. 2001. Structure and design of polymeric surfactant-based drug delivery systems, J Control Release 73:137-172.
46. Torchilin VP, Trubetskoy VS. 1995. Which polymers can make nanoparticulate drug carriers long-circulating, Adv Drug Deliv Rev 16:141-155.
47. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. 2003. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs, Proc Natl Acad Sci USA 100:6039-6044.
48. Trubetskoy VS, Torchilin VP. 1995. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents, Adv Drug Deliv Rev 16:311-320.
49. Trubetskoy VS, Torchilin VP. 1996. Polyethylene glycol based micelles as carriers of therapeutic and diagnostic agents, STP Pharma Sci 6:79-86, 1996.
50. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr., Van Echo DA, Von Hoff DD, Leyland-Jones B. 1990. Hypersensitivity reactions from taxol, J Clin Oncol 8:1263-1268.
51. Weissig V, Lizano C, Torchilin VP. 1998a. Micellar delivery system for dequalinium - A lipophilic cationic drug with anticarcinoma activity, J Liposome Res 8:391-400.
52. Weissig V, Whiteman KR, Torchilin VP. 1998b. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice, Pharm Res 15:1552-1556.
53. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH. 1993. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma, J Chromatogr 621:231-238.
54. Windebank AJ, Blexrud MD, de Groen PC. 1994. Potential neurotoxicity of the solvent vehicle for cyclosporine, J Pharmacol Exp Ther 268:1051-1056.
55. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res 55:3752-3756.
56. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. 1995. Cellular and molecular barriers to gene transfer by a cationic lipid, J Biol Chem 270:18997-19007.